eTable 4. Treatment during the acute phase of COVID-19.
| Total study population | p-value*1 | Post-COVID-19 (Symptom duration ≥ 12 Wochen) | p-value*1 | |||
| No symptoms/ symptoms < 12 weeks n = 739 | Symptoms ≥ 12 weeks(post-COVID-19) n = 720 | Not hospitalized n = 588 | Hospitalized n = 127 | |||
| Hospitalization for acute COVID-19 | ||||||
| Not hospitalized | 685 (92.7) | 588 (81.7) | < 0.001 | 588 | n. a. | n.d. |
| Hospitalized*2 | 48 (6.5) | 127 (17.6) | n.d. | 127 | ||
| Intensive care unit | 6 (0.8) | 25 (3.5) | < 0.001 | n.d. | 25 | |
| Mechanical ventilation | 5 (0.7) | 20 (2.8) | n.d. | 20 | ||
| Medication for acute Covid-19 | ||||||
| No | 576 (77.9) | 412 (57.2) | < 0.001 | 386 (65.6) | 21 (16.7) | < 0.001 |
| Yes | 156 (21.1) | 295 (41.0) | 196 (33.3) | 99 (78.0) | ||
| Antibiotics | 54 (7.3) | 100 (13.9) | < 0.001 | 43 (7.3) | 57 (44.9) | < 0.001 |
| Zinc/selenium/vitamin D | 25 (3.4) | 61 (8.5) | < 0.001 | 49 (8.3) | 12 (9.4) | 0.726 |
| Anticoagulation | 20 (2.7) | 63 (8.8) | < 0.001 | 22 (3.7) | 41 (32.3) | < 0.001 |
| Cortisone | 9 (1.2) | 39 (5.4) | < 0.001 | 26 (4.4) | 13 (10.2) | 0.012 |
| Analgesics *3 | 58 (7.8) | 85 (11.8) | 0.013 | 75 (12.8) | 10 (7.9) | 0.133 |
| Common cold remedies *3 | 10 (1.4) | 18 (2.5) | 0.128 | 16 (2.7) | 2 (1.6) | 0.554*4 |
| Homeopathic preparations *3 | 3 (0.4) | 3 (0.4) | 1.000*4 | 3 (0.5) | 0 (0) | 1.000*4 |
| Other vitamins/trace elements *3 | 5 (0.7) | 10 (1.4) | 0.202 | 10 (1.7) | 0 (0) | 0.223*4 |
| Lung inhalers *3 | 5 (0.7) | 18 (2.5) | 0.006 | 15 (2.6) | 3 (2.4) | 1.000*4 |
| Others *3 | 17 (2.3) | 41 (5.7) | < 0.001 | 24 (4.1) | 17 (13.4) | < 0.001 |
Absolute and relative frequencies are presented as n (%). Information on hospitalization was missing for five patients in the post-COVID-19 group.
*1 The chi-square test was used to calculate p-values unless otherwise indicated. *2 Including intensive care unit and mechanical ventilation.
*3 Information from the optional text boxes.
*4 Fisher’s exact test
n.a., not applicable